Douglas Warner

4.6k total citations · 2 hit papers
79 papers, 2.7k citations indexed

About

Douglas Warner is a scholar working on Plant Science, Ecology and Oncology. According to data from OpenAlex, Douglas Warner has authored 79 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Plant Science, 17 papers in Ecology and 11 papers in Oncology. Recurrent topics in Douglas Warner's work include Agriculture Sustainability and Environmental Impact (16 papers), Sustainable Agricultural Systems Analysis (8 papers) and Bone health and treatments (6 papers). Douglas Warner is often cited by papers focused on Agriculture Sustainability and Environmental Impact (16 papers), Sustainable Agricultural Systems Analysis (8 papers) and Bone health and treatments (6 papers). Douglas Warner collaborates with scholars based in United Kingdom, United States and France. Douglas Warner's co-authors include John Tzilivakis, Kathleen Lewis, Andrew Green, Mike May, K. W. Jaggard, Li Zhu, Paul Cheng, Brian G.M. Durie, Noopur Raje and Kazuyuki Shimizu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Hepatology.

In The Last Decade

Douglas Warner

74 papers receiving 2.6k citations

Hit Papers

An international database for pesticide risk assessments ... 2016 2026 2019 2022 2016 2018 400 800 1.2k

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Douglas Warner United Kingdom 19 1.0k 761 571 453 363 79 2.7k
Ross Sadler Australia 25 602 0.6× 1.0k 1.3× 388 0.7× 469 1.0× 423 1.2× 91 3.5k
Arja Tervahauta Finland 28 459 0.5× 1.4k 1.9× 89 0.2× 158 0.3× 392 1.1× 61 2.7k
Lili Niu China 28 1.1k 1.1× 318 0.4× 92 0.2× 1.0k 2.3× 897 2.5× 114 3.1k
Daniela Baldantoni Italy 29 1.0k 1.0× 633 0.8× 70 0.1× 535 1.2× 160 0.4× 100 2.7k
Xiaoyu Wang China 33 690 0.7× 1.2k 1.6× 73 0.1× 366 0.8× 1.3k 3.5× 170 3.5k
Ligang Wang China 33 378 0.4× 537 0.7× 90 0.2× 95 0.2× 689 1.9× 147 3.1k
Namhyun Chung South Korea 24 673 0.7× 427 0.6× 95 0.2× 628 1.4× 546 1.5× 108 2.5k
Yang Yang China 40 2.0k 2.0× 268 0.4× 113 0.2× 1.0k 2.2× 477 1.3× 219 5.2k
Jin Qian China 25 265 0.3× 271 0.4× 203 0.4× 297 0.7× 1.1k 3.1× 102 2.8k

Countries citing papers authored by Douglas Warner

Since Specialization
Citations

This map shows the geographic impact of Douglas Warner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Warner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Warner more than expected).

Fields of papers citing papers by Douglas Warner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Warner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Warner. The network helps show where Douglas Warner may publish in the future.

Co-authorship network of co-authors of Douglas Warner

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Warner. A scholar is included among the top collaborators of Douglas Warner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Warner. Douglas Warner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rosen, Eric L., Jennifer L. Caswell‐Jin, David Berz, et al.. (2024). 367P Phase I/II dose escalation study evaluating first-in-class eIF4A inhibitor zotatifin in ER+ metastatic breast cancer. Annals of Oncology. 35. S372–S372. 1 indexed citations
3.
Tzilivakis, John, et al.. (2022). An improved indicator framework to assess and optimise ecosystem services provided by permanent grasslands. Ecological Indicators. 146. 109765–109765. 3 indexed citations
7.
Raje, Noopur, Evangelos Terpos, Wolfgang Willenbacher, et al.. (2018). Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. The Lancet Oncology. 19(3). 370–381. 307 indexed citations breakdown →
8.
Liede, Alexander, Sally Wade, Rohini K. Hernandez, et al.. (2018). An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer. Clinical Therapeutics. 40(4). 536–549.e3. 13 indexed citations
9.
Lipton, Allan, Matthew Smith, Karim Fizazi, et al.. (2016). Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents. Clinical Cancer Research. 22(23). 5713–5721. 32 indexed citations
10.
Warner, Douglas, John Tzilivakis, Andrew Green, & Kathleen Lewis. (2016). A guidance tool to support farmers with ecological focus areas – the benefits of agroforestry for ecosystem services and biodiversity. University of Hertfordshire Research Archive (University of Hertfordshire). 1 indexed citations
11.
Tebbutt, Niall C., Dusan Kotasek, Howard A. Burris, et al.. (2015). Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 75(5). 993–1004. 9 indexed citations
12.
Tzilivakis, John, Douglas Warner, Andrew Green, & Kathleen Lewis. (2015). Spatial and temporal variability of greenhouse gas emissions from rural development land use operations. Mitigation and Adaptation Strategies for Global Change. 22(3). 447–467. 2 indexed citations
13.
Vergote, I., Ana Oaknin, J.F. Baurain, et al.. (2014). A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery. European Journal of Cancer. 50(14). 2408–2416. 16 indexed citations
14.
Lewis, Kathleen, et al.. (2013). Review of substances/agents that have direct beneficial effect on the environment: mode of action and assessment of efficacy. EFSA Supporting Publications. 10(6). 7 indexed citations
15.
Peeters, Marc, A. H. Strickland, Mikhail Lichinitser, et al.. (2013). A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. British Journal of Cancer. 108(3). 503–511. 60 indexed citations
16.
Lewis, Kathleen, et al.. (2011). Bio-Pesticides DataBase (BPDB). 2 indexed citations
17.
Ferguson, A. W., et al.. (2004). Phenology and spatial distributions of Dasineura brassicae and its parasitoids in a crop of winter oilseed rape: implications for integrated pest management. Rothamsted Repository (Rothamsted Repository). 7 indexed citations
18.
Jaggard, K. W., John Tzilivakis, Douglas Warner, & Kathleen Lewis. (2004). Beet and the Environment. Rothamsted Repository (Rothamsted Repository). 1 indexed citations
19.
Ferguson, A. W., et al.. (2003). Spatio-temporal distributions of Meligethes aeneus and its parasitoids in an oilseed rape crop and their significance for crop protection. University of Hertfordshire Research Archive (University of Hertfordshire). 8 indexed citations
20.
Warner, Douglas, et al.. (1997). Use of the Alveolar Dead Space Fraction (Vd/Vt) and Plasma D‐dimers to Exclude Acute Pulmonary Embolism in Ambulatory Patients. Academic Emergency Medicine. 4(9). 856–863. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026